# Nomad Power Solutions, Inc.: financial statements, quarterly

NMAD · Nasdaq · CIK 1335105 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nmad.md) · [Financials](/companies/nmad/financials.md) · [Filings](/companies/nmad/filings.md) · [Insiders](/companies/nmad/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nmad/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $k | [356](/filings/0001493152-23-040115.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [132](/filings/0001493152-24-044810.md) | [149 d](/filings/0001641172-25-000208.md) | [119](/filings/0001641172-25-009575.md) | [211](/filings/0001641172-25-022517.md) | [362](/filings/0001493152-25-021941.md) | [34.8 d](/filings/0001493152-26-014052.md) | [91.5](/filings/0001493152-26-023150.md) | [60.6](/filings/0001493152-26-038001.md) | [50.7](/filings/0001493152-25-021941.md) | [52.1 d](/filings/0001493152-26-014052.md) | [333](/filings/0001493152-26-023150.md) | [62.3](/filings/0001493152-26-038001.md) |
| Operating income | $k | [(1,024)](/filings/0001493152-24-044810.md) | [(1,026) d](/filings/0001641172-25-000208.md) | [(967)](/filings/0001641172-25-009575.md) | [(1,009)](/filings/0001641172-25-022517.md) | [(983)](/filings/0001493152-25-021941.md) | [(613) d](/filings/0001493152-26-014052.md) | [(707)](/filings/0001493152-26-023150.md) | [(775)](/filings/0001493152-26-038001.md) | [(1,801)](/filings/0001493152-25-021941.md) | [(1,825) d](/filings/0001493152-26-014052.md) | [(1,987)](/filings/0001493152-26-023150.md) | [(2,350)](/filings/0001493152-26-038001.md) |
| Interest expense | $k | [0.3](/filings/0001493152-24-044810.md) | [10.1 d](/filings/0001641172-25-000208.md) | [7.2](/filings/0001641172-25-009575.md) | [4.2](/filings/0001641172-25-022517.md) | [1.0](/filings/0001493152-25-021941.md) | [4.4 d](/filings/0001493152-26-014052.md) | [3.1](/filings/0001493152-26-023150.md) | [1.8](/filings/0001493152-26-038001.md) | [0.5](/filings/0001493152-25-021941.md) | [3.8 d](/filings/0001493152-26-014052.md) | [3.1](/filings/0001493152-26-023150.md) | [0.9](/filings/0001493152-26-038001.md) |
| Net income | $k | [(1,019)](/filings/0001493152-24-044810.md) | [(1,032) d](/filings/0001641172-25-000208.md) | [(971)](/filings/0001641172-25-009575.md) | [(1,011)](/filings/0001641172-25-022517.md) | [(986)](/filings/0001493152-25-021941.md) | [(618) d](/filings/0001493152-26-014052.md) | [(710)](/filings/0001641172-25-009575.md) | [(776)](/filings/0001641172-25-022517.md) | [(1,980)](/filings/0001493152-25-021941.md) | [(2,613) d](/filings/0001493152-26-014052.md) | [(1,988)](/filings/0001493152-26-038001.md) | [(2,344)](/filings/0001493152-26-038001.md) |
| Diluted EPS | $ per share | [(0.49)](/filings/0001493152-24-044810.md) | not reported | [(0.43)](/filings/0001641172-25-009575.md) | [(0.45)](/filings/0001641172-25-022517.md) | [(0.44)](/filings/0001493152-25-021941.md) | not reported | [(0.29)](/filings/0001493152-26-023150.md) | [(0.29)](/filings/0001493152-26-038001.md) | [(0.33)](/filings/0001493152-25-021941.md) | not reported | [(0.18)](/filings/0001493152-26-023150.md) | [(0.16)](/filings/0001493152-26-038001.md) |
| Basic EPS | $ per share | [(0.49)](/filings/0001493152-24-044810.md) | not reported | [(0.43)](/filings/0001641172-25-009575.md) | [(0.45)](/filings/0001641172-25-022517.md) | [(0.44)](/filings/0001493152-25-021941.md) | not reported | [(0.29)](/filings/0001493152-26-023150.md) | [(0.29)](/filings/0001493152-26-038001.md) | [(0.33)](/filings/0001493152-25-021941.md) | not reported | [(0.18)](/filings/0001493152-26-023150.md) | [(0.16)](/filings/0001493152-26-038001.md) |

- Revenue: not reported
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.1](/filings/0001493152-23-040115.md) | [4.2](/filings/0001493152-24-018337.md) | [3.4](/filings/0001493152-24-018337.md) | [2.6](/filings/0001493152-24-030757.md) | [1.6](/filings/0001493152-24-044810.md) | [1.0](/filings/0001493152-26-014052.md) | [1.4](/filings/0001641172-25-009575.md) | [0.9](/filings/0001641172-25-022517.md) | [2.9](/filings/0001493152-25-021941.md) | [5.1](/filings/0001493152-26-038001.md) | [3.3](/filings/0001493152-26-023150.md) | [12.7](/filings/0001493152-26-038001.md) |
| Current assets | $m | [5.2](/filings/0001493152-23-040115.md) | [4.3](/filings/0001493152-24-044810.md) | [3.6](/filings/0001493152-24-018337.md) | [2.7](/filings/0001493152-24-030757.md) | [1.7](/filings/0001493152-24-044810.md) | [1.1](/filings/0001493152-26-014052.md) | not reported | [1.0](/filings/0001641172-25-022517.md) | [5.4](/filings/0001493152-25-021941.md) | [5.2](/filings/0001493152-26-038001.md) | [3.4](/filings/0001493152-26-023150.md) | [19.3](/filings/0001493152-26-038001.md) |
| Total assets | $m | [5.2](/filings/0001493152-23-040115.md) | [4.3](/filings/0001641172-25-000208.md) | [3.6](/filings/0001493152-24-018337.md) | [2.7](/filings/0001493152-24-030757.md) | [1.7](/filings/0001493152-24-044810.md) | [1.1](/filings/0001493152-26-014052.md) | [1.5](/filings/0001641172-25-009575.md) | [1.2](/filings/0001641172-25-022517.md) | [5.4](/filings/0001493152-25-021941.md) | [12.7](/filings/0001493152-26-038001.md) | [10.9](/filings/0001493152-26-023150.md) | [26.6](/filings/0001493152-26-038001.md) |
| Current liabilities | $m | [0.3](/filings/0001493152-23-040115.md) | [0.3](/filings/0001641172-25-000208.md) | [0.5](/filings/0001493152-24-018337.md) | [0.4](/filings/0001493152-24-030757.md) | [0.3](/filings/0001493152-24-044810.md) | [0.3](/filings/0001493152-26-014052.md) | [0.4](/filings/0001641172-25-009575.md) | [0.5](/filings/0001641172-25-022517.md) | [0.5](/filings/0001493152-25-021941.md) | [1.3](/filings/0001493152-26-038001.md) | [1.2](/filings/0001493152-26-023150.md) | [1.5](/filings/0001493152-26-038001.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [0.3](/filings/0001493152-26-014052.md) | not reported | not reported | not reported | [1.8](/filings/0001493152-26-038001.md) | [1.7](/filings/0001493152-26-023150.md) | [1.7](/filings/0001493152-26-038001.md) |
| Shareholders' equity | $m | [4.9](/filings/0001493152-24-044810.md) | [4.0](/filings/0001493152-25-021941.md) | [3.1](/filings/0001641172-25-022517.md) | [2.2](/filings/0001493152-25-021941.md) | [1.4](/filings/0001493152-25-021941.md) | [0.8](/filings/0001493152-26-014052.md) | [1.2](/filings/0001641172-25-022517.md) | [0.7](/filings/0001493152-25-021941.md) | [4.9](/filings/0001493152-25-021941.md) | [9.7](/filings/0001493152-26-038001.md) | [7.9](/filings/0001493152-26-023150.md) | [23.9](/filings/0001493152-26-038001.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(944) d](/filings/0001493152-24-044810.md) | [(902) d](/filings/0001641172-25-000208.md) | [(789)](/filings/0001641172-25-009575.md) | [(819) d](/filings/0001641172-25-022517.md) | [(958) d](/filings/0001493152-25-021941.md) | [(599) d](/filings/0001493152-26-014052.md) | [(568)](/filings/0001493152-26-023150.md) | [(487) d](/filings/0001493152-26-038001.md) | [(927) d](/filings/0001493152-25-021941.md) | [(1,088) d](/filings/0001493152-26-014052.md) | [(1,831)](/filings/0001493152-26-023150.md) | [(1,612) d](/filings/0001493152-26-038001.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.7](/filings/0001493152-23-040115.md) | [1.7](/filings/0001493152-24-018337.md) | [1.7](/filings/0001493152-24-030757.md) | [2.1](/filings/0001493152-24-044810.md) | [2.2](/filings/0001641172-25-009575.md) | [2.2](/filings/0001641172-25-022517.md) | [2.2](/filings/0001493152-25-021941.md) | [2.5](/filings/0001493152-26-023150.md) | [2.7](/filings/0001493152-26-038001.md) | [6.2](/filings/0001493152-25-021941.md) | [10.9](/filings/0001493152-26-023150.md) | [13.5](/filings/0001493152-26-038001.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 16,101,068 at 2026-08-10, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038001.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.